Similar success was observed with AFM13 (TandAb, CD16A × CD30) when combined with pembrolizumab (ORR = 64.2–73.9%, [211]), achieving an ORR of 88% (n = 30) in relapsed/refractory Hodgkin lymphoma. This evidence concerns the gene FCGR3A and Hodgkins lymphoma.